Biochemical markers for carcinoid disease

CPD Bulletin Clinical Biochemistry

Volumn 8, Issue 1, 2007, Pages 7-12

  Allen, Keith R ^a  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

5 HIAA; Carcinoid; Chromogranin; Serotonin; Tachykinins

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ACETIC ACID; ANGIOPEPTIN; BIOCHEMICAL MARKER; BIOGENIC AMINE; BORIC ACID; CHROMOGRANIN A; CHROMOGRANIN B; HISTAMINE; HISTAMINE DERIVATIVE; HYDROCHLORIC ACID; METHYLIMIDAZOLEACETIC ACID; NEUROKININ A; NEUROPEPTIDE K; OCTREOTIDE; OMEPRAZOLE; SECRETOGRANIN II; SEROTONIN; SOMATOSTATIN DERIVATIVE; TACHYKININ; UNCLASSIFIED DRUG;

CARCINOID; CARCINOID SYNDROME; CHEMOEMBOLIZATION; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; NEUROENDOCRINE TUMOR; PATIENT MONITORING; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RADIOIMMUNOASSAY; REFERENCE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; SEROTONIN BLOOD LEVEL; SEROTONIN METABOLISM;

EID: 34547555629     PISSN: 13678930     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Oberndorfer S. Karzinoide tumoren des dunndarms. Frank Z Pathol 1907; 1:426-29
2. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963; i 238-39
3. Janson ET, Öberg KE. Carcinoid tumours. Baillière's Clin Gastroenterol 1996; 10: 589-601
4. Ardill JES and Erikkson. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocrine-Related Cancer 2003; 10: 459-62
5. Lips CJM, Lentjes EGWM, Höppener JWM. The spectrum of carcinoid tumours and carcinoid syndromes. Ann Clin Biochem 2003; 40: 612-67
6. Bax NDS, Wood HF, Batchelor A, et al; The clinical manifestations of carcinoid disease. World J Surg 1996; 20:142-46
7. Vinik AI, Thompson N, Eckhauser JT. et al; Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. Acta Oncologica 1998; 28: 389-402
8. Davis Z, Moertel CG, McIlrath DC. The malignant carcinoid syndrome. Surgery Gynecol Obstet 1973; 137: 637-44
9. Moyssakis IE, Rallidis LS, Guida GF, Nihoyannopoulos PI. Incidence and evolution of carcinoid syndrome in the heart. J Heart valve dis 1997; 6: 625-30
10. Newton JN, Swerdlow AJ, dos Santos Silva IM, et al; The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer 1994; 70: 939-42
11. Taupenot L, Harper KL, O'Connor DT. The Chromogranin-Secretogranin Family. New Eng J Med 2003; 348: 1134-49
12. Nobels FEE, Kwekkeboom DJ, Bouillon R, et al; Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 1998; 28: 431-40
13. Baudin E, Bidart JM, Bachelot A, et al; Impact of chromogranin A measurement in the work-up of neuroendocrine tumours. Ann Oncol 2001; 12 (suppl 2): S79-S82
14. Stivanello M, Berruti A, Torta M, et al; Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol 2001; 12 (Suppl 2); S73-S77
15. Seregni E, Ferrari L, Bajetta E, et al; Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001; 12 (Suppl 2): S69-S72
16. Stridsberg M, Eriksson B, Öberg K, et al; A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003; 177:337-341
17. Ramage JK, Davies AHG, Ardill J, et al; Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54: 1-16
18. Janson ET, Holmberg L, Stridsberg M, et al; Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral centre. Ann Oncol 1997; 8: 685-690
19. Ferrero-Pous, Hersant AM, Pecking A, et al; Serum chromogranin-A in advanced prostate cancer. BJU International 2001; 80: 790-96
20. Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney International 1990; 37: 955-64
21. Giusti M, Sidoti M, Augeri C, et al; Effect of short-term treatment with low dosage of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinology 2004; 150: 299-303
22. Drougas JG, Anthony LB, Blair TK, et al; Hepatic artery chemoembolisation for management of patients with advanced metastatic carcinoid tumors. Am J Surg 1998; 175: 408-12
23. Søndenaa K, Sen J, Heinle F, et al; Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases; preliminary report. World J Surg 2004; 28: 890-5
24. Theodorsson-Norheim E, Norheim I, Öberg K, et al; Neuropeptide K: A major tachykinin in plasma and tumor tissue from carcinoid patients. Biochem Biophys Res Comms 1985; 131: 77-83
25. Turner GB. Johnston BT, McCance DR, et al; Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut 2006; 55: 1586-91
26. Kema IP, de Vries EGE, Muskiet FAJ. Clinical chemistry of serotonin and metabolites. J Chromatogr B 2000; 747; 33-48
27. Castiello RJ, Lynch PJ. Pellagra and the carcinoid syndrome. Arch Dermatol 1972; 105: 574-7
28. Ramage JK, Davies AHG, Ardill J, et al; Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid)tumours. Gut 2005; 54 (Suppl IV) iv1-iv16
29. Deacon AC. The measurement of 5-hydroxyindoleacetic acid in urine. Ann Clin Biochem 1994; 31: 215-32
30. Manini P, Andreoli R, Cavazzini S, et al; Liquid chromatography-electrospray tandem mass spectrometry of acidic monamine metabolitas. J Chromatogr B Biomed Sci Appl 2000; 744: 423-31
31. Oberg K, Janson ET, Erikkson B. Tumour markers in neuroendocrine tumours. J Gastroenterol Hepatol 1999; 31 Suppl 2; 160-162
32. Søndenaa K, Sen J, Heinle F, et al; Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report. World J Surg 2004; 28: 890-5
33. Strosberg JR, Junsung C, Cantor AB, et al; Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumours. Cancer Control 2006; 13: 72-8
34. Moertel CG, Johnson CM, McKusick MA, et al; The management of patients with advanced carcinoid tumours and islet cell carcinomas. Ann Int Med 1994; 120: 302-9
35. Drougas JG, Anthony LB, Blair TK, et al; Hepatic artery chemoembolisation for management of patients with advanced metastatic carcinoid tumours. Amer J Surg 1998; 175: 406-12
36. Kvols LK, Moertel CG, O'Connell MJ, et al; Treatment of the malignant carcinoid syndrome. Evaluation of a long-tarm somatostatin analogue. New Eng J Med 1986; 315: 663-6
37. Ruszniewski P, Ducreux M, Chayvialle JA, et al; Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996; 39: 279-283
38. Jansen ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncologica 1993; 32: 225-9
39. Souquet JC, Sassolas G, Forichon J, et al; Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumours and in carcinoid syndrome. Cancer 1987; 59: 1654-60
40. Carling RS, Degg TJ, Allen KR, et al; Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease. Ann Clin Biochem 2002; 39: 577-82
41. Jaffe BM. Prostaglandins and serotonin: nonpeptide diarrheoganic hormones. World J Surg 1979; 3: 565-78
42. Moller JE, Connolly HM, Rubin J, etal; Factors associated with progression of carcinoid heart disease. New Eng J Med 2003; 348: 1005-1016
43. Feldman JM. Serotonin metabolism in patients with carcinoid tumors: incidence of 5-hydroxytryptophan-secreting tumors. Gastroenterol 1978; 75: 1109-1114.
44. Kema IP, Meijer WG, Gert Meiborg WG, et al; Profiling of tryptophan-related plasma indoles in patients with carcinoid tumors by automated, on-Line, solid-phase extraction and HPLC with fluorescence detection. Clin Chem 2001: 47:1811-20
45. Meijer WG, Kema IP, Volmer M, et al; Discriminating capacity of indole markers in the diagnosis of carcinoid tumours. Clin Chem 2000; 46: 1588-96
46. Pussard E, Guigueno N, Adam O, et al; Validation of HPLC-amperometric detection to measure serotonin in plasma, whole blood and urine. Clin Chem 1996; 42: 1086-91
47. Kema IP, de Vries EGE, Muskier FAJ. Clinical chemistry of serotonin and metabolites J Chromatogr B 2000; 747: 33-48
48. Mayo Clinic Reference Services http://www.mayoreferenceservices.org/
49. Allen KR, Degg TJ, Anthoney DA, et al; Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-HIAA: 3 case examples. Ann Clin Biochem (In press)
50. Kema IP, Schellings AMJ, Meiborg G, et al; Influence of a serotonin and dopamine-rich diet on platelet serotonin content and urinary excretion of biogenic amines and their metabolites. Clin Chem 1992; 38: 1730-36
51. Ahlman H, Kölby L, Lundell L, et al; Grimelius L, Nilsson O. Clinical management of gastric carcinoid tumours. Digestion 1994; 55: 77-85
52. Gustafen J, Boesby S, Man WK. Histamine in carcinoid syndrome. Agents actions 1988; 25: 1-3
53. Grossman M, Trautmann ME, Poerti S, et al; Alpha-subunit and human chorionic gonadotrophin-beta immunoroactivity in patients with malignant endocrine gastroenteropancreatic tumours. Eur J Clin Invest 1994; 24: 131-6
54. Tormey Wp, Fitzgerald RJ. The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Postgrad Med J 1995; 71: 542-5